Anesthesia Management in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
- Conditions
- Cytoreductive SurgeryHyperthermic Intraperitoneal ChemotherapyAnesthesia
- Registration Number
- NCT06398678
- Lead Sponsor
- Sanliurfa Mehmet Akif Inan Education and Research Hospital
- Brief Summary
A combined approach of cytoreductive surgery (SRC) and hyperthermic intraperitoneal chemotherapy (HIPEC) represents a potential treatment option for patients diagnosed with primary or secondary gastrointestinal or gynaecological malignancies with peritoneal involvement. While the surgical phase of the operation macroscopically addresses the cancerous tissue, the HIPEC phase targets the microscopic tumour cells that remain after surgery (1). The surgical procedure known as SRC and HIPEC is one of the most complex surgical procedures, presenting numerous challenges for both the surgical and anaesthesia teams. The haemodynamic, haematological and metabolic changes that occur before, during and in the early postoperative period are associated with an increased risk of morbidity and mortality. It is therefore crucial for anaesthesia management to maintain normovolemia during surgery, compensate for hypothermia in the surgical phase and hyperthermia in the HIPEC phase, and maintain metabolic and haemodynamic balance throughout the entire procedure.
The objective of this study was to retrospectively examine the anaesthesia management and clinical outcomes in patients who underwent cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in order to create literature information that can facilitate the early recognition and prevention of haemodynamic, haematological and metabolic problems that occur especially in the intraoperative and postoperative period.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 50
- patients with primary or secondary gastrointestinal or gynecologic malignancies with peritoneal involvement.
- Over 18 years of age
- Over 80 years of age
- those with heart, lung and liver diseases
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method fluid transfusion amounts during the operation The quantity of fluid transfusion administered to the patient during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy will be determined from documented records in millilitres.
Anesthesia Management in Hyperthermic Intraperitoneal Chemotherapy 01/01/2020 - 01/01/2024 anaesthesia management in cytoreductive surgery and while hypertermic intraperitoneal chemotherapy
procedure times during the operation The duration of the surgical procedure applied to the patient during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy will be determined from the documents recorded in minutes.
30-day mortality and morbidity post-operative 30 days The morbidity and mortality rate observed in the patient within 30 days of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy will be quantified as a percentage based on the documented records.
blood replacements during the operation The quantity and type of blood and blood products transfused to the patient during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy will be determined from documented records in millilitres.
perioperative complications during the operation The potential complications associated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy will be identified from the documented records.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University of Health Science Turkey Sanliurfa Mehmet Akif Inan Training and Research Hospital
🇹🇷Şanlıurfa, Turkey